Supplementary tables for "Cutaneous T-cell lymphoma following dupilumab use: A systematic review"

In this systematic review, we aimed to evaluate reported cases of CTLC following dupilumab use and identify characteristics, histologic findings, and timeline of CTCL development. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was performed using PubMed and Embase databases (Figure 1). Key search terms were: “mycosis fungoides and dupilumab”, “cutaneous T cell lymphoma and dupilumab”, “sezary and dupilumab”. Additional relevant studies were identified using the reference lists from the included articles. Studies reporting at least one patient who developed CTCL, such as mycosis fungoides (MF) or sezary syndrome (SS), after dupilumab treatment for an initial diagnosis other than CTCL, or studies demonstrating exacerbation of CTCL with dupilumab were included. Letters from the editor and cases reporting clinical improvement of MF or SS after dupilumab therapy were excluded. Two reviewers (A.P. and A.E.) independently assessed the articles. Data extracted included: study type, patient demographics, preliminary diagnosis, initial treatment, duration of dupilumab treatment, clinical signs and symptoms, sites involved, body surface area involved, TNM classification/tumor stage, pre- and post-dupilumab histopathologic features, time to biopsy after dupilumab, immunohistochemical phenotype, TCR gene rearrangement, final diagnosis, treatment, and clinical outcome.

本系统综述旨在评估度普利尤单抗使用后发生皮肤T细胞淋巴瘤（cutaneous T cell lymphoma, CTCL）的报告病例（注：原文中“CTLC”疑为“CTCL”的笔误），并明确CTCL发生的特征、组织学表现及时间线。研究遵循系统综述与荟萃分析优先报告条目（Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PRISMA）指南，检索PubMed和Embase数据库（图1）。核心检索词包括：“蕈样肉芽肿与度普利尤单抗”、“皮肤T细胞淋巴瘤与度普利尤单抗”、“塞扎里与度普利尤单抗”。通过纳入文献的参考文献列表进一步筛选相关研究。纳入标准为：报告至少1例初始诊断非CTCL的患者在接受度普利尤单抗治疗后发生CTCL（如蕈样肉芽肿（mycosis fungoides, MF）或塞扎里综合征（sezary syndrome, SS））的研究，或显示度普利尤单抗加重CTCL的研究。排除标准为：编辑来信及报告度普利尤单抗治疗后MF或SS临床改善的病例。两名评价者（A.P.与A.E.）独立对文献进行评估。提取的数据包括：研究类型、患者人口统计学特征、初步诊断、初始治疗、度普利尤单抗治疗持续时间、临床症状与体征、受累部位、受累体表面积、TNM分期/肿瘤阶段、度普利尤单抗治疗前后的组织病理学特征、治疗后活检时间、免疫组化表型、TCR基因重排、最终诊断、治疗方案及临床结局。